Dr. Chari on Impact of CAR T Cells in Myeloma

Video

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of CAR T-cell therapy in myeloma.

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in patients with myeloma.

Recent data with CAR T cells have been very encouraging, particularly with the phase I trial of bb2121 that was presented at the 2018 ASCO Annual Meeting. In a penta-refractory patient population, median progression-free survival was almost 1 year and overall response rate was 96%. Chari says this is important because these results are being seen with just 1 intervention of CAR T, unlike other treatment strategies that continue over an extended period of time.

Something to keep in mind about CAR T-cell therapy is the toxicity, especially cytokine release syndrome. It is also difficult to compare outcomes with other off-the-shelf treatment options because there is selection bias with patients who enroll for CAR T cells. Other unanswered questions with this treatment are shortening manufacturing time, getting larger patient populations enrolled, and if this therapy can be combined with other treatment.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.